Groundbreaking medical technology with a Swedish heritage
Non-invasive measurement of gases
The innovative technology in Neola® that allows for continuous monitoring and surveillance of preterm born infants’ lungs is called GASMAS (gas in scattering media absorption spectroscopy) – a groundbreaking method for measuring gases in body cavities that has been patented by Neola Medical. GASMAS was originally developed by researchers at Division of Atomic Physics at Lund University and has been further refined by Neola Medical.
GASMAS’ biomedical application currently enables non-invasive measurement of lung volume changes and oxygen gas concentration directly in the lungs. This method is completely revolutionary and unique and is based on the specific light absorption by oxygen and water vapor gas molecules compared to the absorption by liquid and solid compounds of tissue.
GASMAS is currently being applied in Neola®, a medical device that can monitor the lungs of preterm born infants. A clinically proven and commercialized GASMAS technology has potential to fill even more gaps in health care by offering a safe and non-invasive method to measure volume changes and composition of gases inside cavities of the body.
GASMAS technology in Neola® that allows for non-invasive continuous lung monitoring of preterm born babies.
Professor Katarina Svanberg and Professor Sune Svanberg
The technology founders
The technology founders include Professor Sune Svanberg, a distinguished physicist who served on the Nobel Prize election committee for many years, alongside his wife, Professor Katarina Svanberg, a renowned medical doctor.
The gas measurement technology is based on years of research at Lund University. The first lung measurements using the GASMAS technology were conducted as part of a research project and were published in 2011 by Neola Medical’s Chairman of the Board, Märta Lewander Xu, during her doctoral studies under the supervision of Professor Sune Svanberg and with Professor Katarina Svanberg as co-supervisor.
For Investors
We are on a journey to revolutionize neonatal intensive care
Learn more about investing in Neola Medical
About Neola Medical
Neola Medical AB (publ) is revolutionizing neonatal intensive care with Neola®, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume changes and oxygen gas concentration. Neola® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.
Sweden, HQ
Neola Medical AB
Ideon Gateway
Scheelevägen 27
223 63 Lund
info@neolamedical.com
U.S. Office
Neola Medical, Inc.
Nordic Innovation House
470 Ramona Street PMB
Palo Alto CA 94301-1707
info@neolamedical.com